How is ewing sarcoma treated

A stem cell transplant might be an option for some patients with Ewing tumors that are unlikely to be cured with other treatments.

Treating Ewing tumors requires a team approach that includes different types of specialists. For adults with Ewing tumors, treatment is typically done at a major cancer center. Doctors on the treatment team might include:.

For both adults and children, the team might also include other doctors, physician assistants PAs , nurse practitioners NPs , nurses, psychologists, social workers, physical therapists and other rehabilitation specialists, and other health professionals. The treatment for Ewing tumors is often effective, but it can also cause serious side effects. If time allows, getting a second opinion from another doctor experienced with Ewing tumors is often a good idea.

This can give you more information and help you feel more confident about the treatment plan you choose. Once treatment starts, members of the treatment team can help you deal with side effects, stress, financial aid, and other issues related to the treatment. For cancer in children and teens, many of these issues can be more complex. As a parent, taking care of a child with cancer can be a very big job. These centers offer the most up-to-date-treatment by conducting clinical trials studies of promising new therapies.

Late effects can include heart and lung problems, emotional and learning difficulties, growth issues and second malignancies associated with chemotherapy or radiation. For example, children treated for Ewing sarcoma have a higher risk than the average population of developing solid tumors or leukemia later in life. Some treatments may later affect fertility.

If this side effect is permanent, it will cause infertility the inability to have children. Both men and women can be affected by fertility issues. If Ewing sarcoma recurs, it usually happens within a few years of treatment. About 30 percent of patients will have a recurrence within the first five years. Once cancer recurs, it becomes much more difficult to treat. The same chemotherapy drugs that were used during initial treatment cannot be used again due to toxicity concerns.

Typically, a relapse of Ewing sarcoma prompts physicians to explore nontraditional or newer treatment options. As advances in targeted and immunotherapies continue, the hope is that prognosis for recurrent Ewing sarcoma will improve.

Proton therapy is used to treat certain tumors in children and adults. Health Home Conditions and Diseases Sarcoma. What is Ewing sarcoma? Under the microscope, Ewing sarcoma cells appear small, round and blue. Who gets Ewing Sarcoma?

Ewing sarcoma is a very rare cancer in adults. What causes Ewing sarcoma? What are the symptoms of Ewing sarcoma? How is Ewing sarcoma diagnosed? Diagnostic tests for Ewing sarcoma may include the following: Multiple imaging tests : X-ray. This diagnostic test uses invisible electromagnetic energy beams to produce images of internal tissues, bones and organs on film.

Radionuclide bone scan. Pictures of the bone are captured with a special camera and are used to detect tumors and bone abnormalities. Magnetic resonance imaging MRI. This diagnostic procedure uses a combination of large magnets, radio frequencies and a computer to produce detailed images of organs and structures within the body.

This test is often done to see if the tumor has spread to the nearby soft tissues. This diagnostic imaging procedure uses a combination of X-rays and computer technology to produce horizontal, or axial, images often called slices of the body.

A CT scan shows detailed images of any part of the body, including the bones, muscles, fat and organs. Positron emission tomography PET scan. For this test, radioactive-tagged glucose sugar is injected into the bloodstream. Tissues that use the glucose more than normal tissues such as tumors can be detected by a scanning machine. However, chemotherapy for Ewing sarcoma is usually injected into a vein or muscle; it is rarely given by mouth.

When possible, treatment for Ewing sarcoma begins with chemotherapy. After this first chemotherapy is finished, the doctor may use localized surgery or radiation therapy see below followed by more chemotherapy to get rid of any remaining cancer cells.

A chemotherapy regimen, or schedule, usually consists of a specific number of cycles given over a set period of time. A patient may receive 1 drug at a time or combinations of different drugs given at the same time. For Ewing sarcoma that has not spread to other parts of the body, the standard schedule is chemotherapy every 2 weeks.

Patients with metastatic Ewing sarcoma may also be treated with the above medications and dactinomycin Cosmegen. The side effects of chemotherapy depend on the individual and the dose used, but they can include fatigue, risk of infection, nausea and vomiting, hair loss, loss of appetite, and diarrhea. These side effects usually go away after treatment is finished. Children and young adults receiving chemotherapy for Ewing sarcoma may be at risk for developing neutropenia , which is an abnormally low level of a type of white blood cell called neutrophils.

All white blood cells help the body fight infection. The doctor may give the patient medications to increase their white blood cell levels. These medications are called white blood cell growth factors, also known as colony-stimulating factors CSFs. Treating neutropenia is an important part of the overall treatment plan.

Surgery is the removal of the tumor and some surrounding healthy tissue during an operation. When possible, surgical removal of the tumor should happen after chemotherapy. Surgery may also be needed to remove any remaining cancer cells after chemotherapy or radiation therapy. An orthopedic oncologist is usually the doctor who will perform the surgery. Often, a tumor can be removed without causing disability.

Bone grafts from other parts of the body may help reconstruct the limb, and a prosthesis made of metal or plastic bones or joints can replace lost tissue. Physical therapy after surgery can help children and young adults learn to use the limb again. Support services are available to help patients cope with the emotional effects of the loss of a limb.

Learn more about rehabilitation. Before surgery, talk with the health care team about possible side effects from the specific surgery your child will have. Learn more about the basics of cancer surgery.

Radiation therapy is the use of high-energy x-rays or other high-energy particles to destroy tumor cells. A doctor who specializes in giving radiation therapy to treat cancer is called a radiation oncologist. For Ewing sarcoma, radiation therapy is used when surgery is not possible or if surgery did not remove all of the tumor cells, as well as when chemotherapy was not effective.

The most common type of radiation treatment is called external-beam radiation therapy, which is radiation given from a machine outside the body. When radiation therapy is given using implants, it is called internal radiation therapy or brachytherapy. A radiation therapy regimen, or schedule, usually consists of a specific number of treatments given over a set period of time. Intraoperative radiation therapy, which is given inside the body during surgery, is being studied in clinical trials.

Side effects from radiation therapy may include fatigue, mild skin reactions, upset stomach, and loose bowel movements. Most side effects go away soon after treatment is finished. In the long term, radiation therapy can also interfere with normal bone growth and increase the risk of developing a secondary cancer. Learn more about the basics of radiation therapy. For Ewing sarcoma, a bone marrow transplant is an approach that is still being studied to find out if it is an effective treatment option.

It should only be done as part of a clinical trial. Flow cytometry for cells that express the CD99 antigen was not sufficiently sensitive to serve as a reliable biomarker. A more sensitive technique that utilized patient-specific primers designed after identification of the specific translocation breakpoint in combination with droplet digital PCR reported a sensitivity of 0. Additional study is required to determine whether circulating cell-free DNA will have clinical utility as a biomarker for Ewing sarcoma to monitor disease status and response to therapy.

Ewing sarcoma belongs to the group of neoplasms commonly referred to as small round blue cell tumors of childhood. The individual cells of Ewing sarcoma contain round-to-oval nuclei, with fine dispersed chromatin without nucleoli. The cytoplasm varies in amount, but in the classic case, it is clear and contains glycogen, which can be highlighted with a periodic acid-Schiff stain.

The tumor cells are tightly packed and grow in a diffuse pattern without evidence of structural organization. Tumors with the requisite translocation that show neuronal differentiation are not considered a separate entity, but rather, part of a continuum of differentiation. CD99 is a surface membrane protein that is expressed in most cases of Ewing sarcoma and is useful in diagnosing these tumors when the results are interpreted in the context of clinical and pathologic parameters.

Refer to the Undifferentiated Small Round Cell [Ewing-like] Sarcomas section of this summary for more information about the cellular classification of other undifferentiated small round cell sarcomas. The detection of a translocation involving the EWSR1 gene on chromosome 22 band q12 and any one of a number of partner chromosomes is the key feature in the diagnosis of Ewing sarcoma refer to Table 2.

The significance of these alternate partners is not known. Besides these consistent aberrations involving the EWSR1 gene at 22q12, additional numerical and structural aberrations have been observed in Ewing sarcoma, including gains of chromosomes 2, 5, 8, 9, 12, and 15; the nonreciprocal translocation t 1;16 q12;q Trisomy 20 may be associated with a more aggressive subset of Ewing sarcoma.

Three papers have described the genomic landscape of Ewing sarcoma and all show that these tumors have a relatively silent genome, with a paucity of mutations in pathways that might be amenable to treatment with novel targeted therapies. Enlarge Figure 1. A comprehensive profile of the genetic abnormalities in Ewing sarcoma and associated clinical information.

Key clinical characteristics are indicated, including primary site, type of tissue, and metastatic status at diagnosis, follow-up, and last news. The numbers of structural variants SV and single-nucleotide variants SNV as well as indels are reported in grayscale. The presence of the main copy-number changes, chr 1q gain, chr 16 loss, chr 8 gain, chr 12 gain, and interstitial CDKN2A deletion is indicated. Listed last are the most significant mutations and their types. Ewing sarcoma translocations can all be found with standard cytogenetic analysis.

A more rapid analysis looking for a break apart of the EWSR1 gene is now frequently done to confirm the diagnosis of Ewing sarcoma molecularly. In addition, other small round tumors also contain translocations of different ETS family members with EWSR1 , such as desmoplastic small round cell tumor, clear cell sarcoma, extraskeletal myxoid chondrosarcoma, and myxoid liposarcoma, all of which may be positive with a EWSR1 fluorescence in situ hybridization FISH break-apart probe.

The authors do not recommend relying solely on EWSR1 break-apart probes for analyzing small round blue cell tumors with strong immunohistochemical positivity for CD Small round blue cell tumors of bone and soft tissue that are histologically similar to Ewing sarcoma but do not have rearrangements of the EWSR1 gene have been analyzed and translocations have been identified. There are too few cases associated with each translocation to determine whether the prognosis for patients with these small round blue cell tumors is distinct from the prognosis of patients with Ewing sarcoma of similar stage and site.

Other undifferentiated round cell sarcomas are characterized by a CIC-DUX4 fusion resulting from a recurrent t 4;19 or t 10; Genome-wide association studies have identified susceptibility loci for Ewing sarcoma at 1p Three new susceptibility loci have been identified at 6p Pretreatment staging studies for Ewing sarcoma may include the following:.

Despite the fact that CT and MRI are both equivalent in terms of staging, use of both imaging modalities may help radiation therapy planning. In certain studies, determination of pretreatment tumor volume is an important variable. In one institutional study, 18F-FDG PET had a very high correlation with bone scan; the investigators suggested that it could replace bone scan for the initial extent of disease evaluation.

Bone marrow aspiration and biopsy have been considered the standard of care for Ewing sarcoma. The need for routine use of bone marrow aspirates and biopsies in patients without bone metastases is now in question. For Ewing sarcoma, the tumor is defined as localized when, by clinical and imaging techniques, there is no spread beyond the primary site or regional lymph node involvement.

Continuous extension into adjacent soft tissue may occur. If there is a question of regional lymph node involvement, pathologic confirmation is indicated. It is important that patients be evaluated by specialists from the appropriate disciplines e.

Appropriate imaging studies of the site are obtained before biopsy. To ensure that the incision is placed in an acceptable location, the surgical or orthopedic oncologist who will perform the definitive surgery is involved in the decision regarding biopsy-incision placement. This is especially important if it is thought that the lesion can subsequently be totally excised after initial systemic therapy or if a limb salvage procedure may be attempted.

It is almost never appropriate to attempt a primary resection of Ewing sarcoma. With rare exceptions, Ewing sarcoma is sensitive to chemotherapy and will respond to initial systemic therapy, which makes ultimate surgery easier and safer.

Primary surgery incurs the risk of tumor spread to surrounding tissues, which is reduced by the use of initial systemic therapy. Biopsy should be from soft tissue as often as possible to avoid increasing the risk of fracture.

It is important to obtain fresh tissue, whenever possible, for cytogenetics and molecular pathology. A second option is to perform a needle biopsy, as long as adequate tissue is obtained for molecular biology and cytogenetics. Table 3 describes the treatment options for localized, metastatic, and recurrent Ewing sarcoma. In patients who undergo surgery, surgical margins and histologic response are considered in planning postoperative therapy.

Patients with metastatic disease often have a good initial response to preoperative chemotherapy, but in most cases, the disease is only partially controlled or recurs. Adequate local control for metastatic sites, particularly bone metastases, may be an important issue. Multidrug chemotherapy for Ewing sarcoma always includes vincristine, doxorubicin, ifosfamide, and etoposide. Most protocols also use cyclophosphamide and some incorporate dactinomycin.

The mode of administration and dose intensity of cyclophosphamide within courses differs markedly between protocols. Protocols in the United States generally alternate courses of vincristine, cyclophosphamide, and doxorubicin VDC with courses of ifosfamide and etoposide IE ,[ 8 ] while, for many years, European protocols generally combined vincristine, doxorubicin, and an alkylating agent with or without etoposide in a single treatment cycle.

Treatment approaches for Ewing sarcoma and therapeutic aggressiveness must be adjusted in order to maximize local control while also minimizing morbidity. Surgery is the most commonly used form of local control. However, in the immature skeleton, radiation therapy can cause subsequent deformities that may be more morbid than deformities from surgery.

When complete surgical resection with pathologically negative margins cannot be obtained, postoperative radiation therapy is indicated.

A multidisciplinary discussion between the experienced radiation oncologist and the surgeon is necessary to determine the best treatment options for local control for a given case. For some marginally resectable lesions, a combined approach of preoperative radiation therapy followed by resection can be used.

Timing of local control may impact outcome. A retrospective review from the National Cancer Database identified 1, patients with Ewing sarcoma. The difference in OS according to time to local therapy was more important in patients who received radiation therapy alone. For patients with metastatic Ewing sarcoma, any benefit of combined surgery and radiation therapy compared with either therapy alone for local control is relatively less substantial because the overall prognosis of these patients is much worse than the prognosis of patients who have localized disease.

Randomized trials that directly compare surgery and radiation therapy do not exist, and their relative roles remain controversial. Although retrospective institutional series suggest superior local control and survival with surgery than with radiation therapy, most of these studies are compromised by selection bias.

An analysis using propensity scoring to adjust for clinical features that may influence the preference for surgery only, radiation only, or combined surgery and radiation demonstrated that similar EFS is achieved with each mode of local therapy.

The study did not prospectively define criteria for the selection of local-control modalities, and the investigators did not have access to information that would allow them to clarify why decisions for local-control modalities were made. In patients with bone tumors who underwent surgical treatment— after controlling for tumor site in the pelvis, tumor volume, and surgical margin status—patients who did not undergo complete removal of the affected bone HR, 5. For patients who undergo gross-total resection with microscopic residual disease, a radiation therapy dose of In summary, surgery is chosen as definitive local therapy for suitable patients, but radiation therapy is appropriate for patients with unresectable disease or those who would experience functional or cosmetic compromise by definitive surgery.

The possibility of impaired function or cosmesis needs to be measured against the possibility of second tumors in the radiation field. Adjuvant radiation therapy should be considered for patients with residual microscopic disease or inadequate margins. When preoperative assessment has suggested a high probability that surgical margins will be close or positive, preoperative radiation therapy has achieved tumor shrinkage and allowed surgical resection with clear margins.

For patients with a high risk of relapse with conventional treatments, certain investigators have utilized high-dose chemotherapy with hematopoietic stem cell transplant HSCT as consolidation treatment, in an effort to improve outcome. Both study arms were compromised by the potential for selection bias for patients who were eligible for and accepted randomization, which may limit the generalizability of the results.

This regimen is less dose intensive than the regimen employed in COG studies. Results from this study include the following:. The advantage of high-dose therapy as consolidation for patients with a poor response to initial treatment with a less intensive regimen cannot be extrapolated to a population of patients who received a more intensive treatment regimen as initial therapy.

Multiple analyses have evaluated diagnostic findings, treatment, and outcome of patients with bone lesions at the following anatomic primary sites:. Extraosseous Ewing sarcoma is biologically similar to Ewing sarcoma arising in bone. Historically, most children and young adults with extraosseous Ewing sarcoma were treated on protocols designed for the treatment of rhabdomyosarcoma.

This is important because many of the treatment regimens for rhabdomyosarcoma do not include an anthracycline, which is a critical component of current treatment regimens for Ewing sarcoma. Currently, patients with extraosseous Ewing sarcoma are eligible for studies that include Ewing sarcoma of bone.

Cutaneous Ewing sarcoma is a soft tissue tumor in the skin or subcutaneous tissue that seems to behave as a less-aggressive tumor than primary bone or soft tissue Ewing sarcoma.

Tumors can form throughout the body, although the extremity is the most common site, and they are almost always localized. Cancer in children and adolescents is rare, although the overall incidence has been slowly increasing since This multidisciplinary team approach incorporates the skills of the following health care professionals and others to ensure that children receive treatment, supportive care, and rehabilitation that will achieve optimal survival and quality of life:. Refer to the PDQ Supportive and Palliative Care summaries for specific information about supportive care for children and adolescents with cancer.

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of pediatric patients with cancer. Clinical trials for children and adolescents with cancer are generally designed to compare potentially better therapy with current standard therapy.

Most of the progress made in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website. Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment.

Refer to the PDQ summary on Late Effects of Treatment for Childhood Cancer for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors. Standard treatment options for localized Ewing sarcoma include the following:.

There was no increase in toxicity observed with the every 2-week schedule. Decisions regarding the optimal modality for local control for an individual patient involve consideration of the following:.

An analysis using propensity scoring a method that adjusts for the inherent selection bias of the location and size of the tumor to adjust for clinical features that may influence the preference for surgery only, radiation only, or combined surgery and radiation demonstrated that similar EFS rates are achieved with each mode of local therapy after propensity adjustment. Surgery is generally the preferred approach if the lesion is resectable. The apparent superiority may represent selection bias.

Pathologic fracture at the time of diagnosis does not preclude surgical resection and is not associated with adverse outcome. Radiation therapy is delivered in a setting in which stringent planning techniques are applied by those experienced in the treatment of Ewing sarcoma. Such an approach will result in local control of the tumor with acceptable morbidity in most patients. The radiation dose may be adjusted depending on the extent of residual disease after the initial surgical procedure.

When no surgical resection is performed, radiation therapy is generally administered in fractionated doses totaling approximately A randomized study of 40 patients with Ewing sarcoma using For patients with residual disease after an attempt at surgical resection, the Intergroup Ewing Sarcoma Study INT recommended 45 Gy to the original disease site plus a No radiation therapy was recommended for those who have no evidence of microscopic residual disease after surgical resection.

Comparison of proton-beam radiation therapy and intensity-modulated radiation therapy IMRT treatment plans has shown that proton-beam radiation therapy can spare more normal tissue adjacent to Ewing sarcoma primary tumors than IMRT.

Because patient numbers are small and follow-up is relatively short, it is not possible to determine whether the risk of local recurrence might be increased by reducing radiation dose in tissue adjacent to the primary tumor. Higher rates of local failure are seen in patients older than 14 years who have tumors larger than 8 cm in length. Patients with pleural invasion, pleural effusion, or intraoperative contamination were assigned to hemithorax radiation therapy.

EFS was longer for patients who received hemithorax radiation, but the difference was not statistically significant. In addition, most patients with primary vertebral tumors did not receive hemithorax radiation and had a lower probability for EFS. Radiation therapy is associated with the development of subsequent neoplasms.

Use our advanced clinical trial search to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. General information about clinical trials is also available.